239 related articles for article (PubMed ID: 35018582)
21. The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy.
Aluf O; Parente S; Radin M; Campa L; Gazzola V; Olugbogi A; Tesio N; Ugo H; Zanetti E; Zevallos C; Versino E; Lembo D; Roccatello D; Sciascia S
Lupus; 2024 Jan; 33(1):75-82. PubMed ID: 38116607
[TBL] [Abstract][Full Text] [Related]
22. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome?
Ghirardello A; Doria A; Ruffatti A; Rigoli AM; Vesco P; Calligaro A; Gambari PF
Ann Rheum Dis; 1994 Feb; 53(2):140-2. PubMed ID: 8129460
[TBL] [Abstract][Full Text] [Related]
23. The impact of antiphospholipid antibodies in Takayasu arteritis.
Şentürk EF; Erden A; Sarı A; Armağan B; Kılıç L; Kalyoncu U; Karadağ Ö; Bilgen ŞŞA; Kiraz S; Ertenli Aİ; Akdoğan A
Turk J Med Sci; 2023 Feb; 53(1):199-205. PubMed ID: 36945962
[TBL] [Abstract][Full Text] [Related]
24. [Value of IgA antiphospholipid antibodies in diagnosis of the antiphospholipid syndrome].
Yang B; Zhao JL; Huang ZC; Su ZZ; Li MT; Zeng XF; Hu CJ
Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(41):3404-3410. PubMed ID: 34758544
[No Abstract] [Full Text] [Related]
25. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
[TBL] [Abstract][Full Text] [Related]
26. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses.
Radway-Bright EL; Ravirajan CT; Isenberg DA
Rheumatology (Oxford); 2000 Apr; 39(4):427-31. PubMed ID: 10817777
[TBL] [Abstract][Full Text] [Related]
27. [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].
Marai I; Levi Y; Godard G; Shoenfeld Y
Harefuah; 2001 Jun; 140(6):495-500, 565. PubMed ID: 11420848
[TBL] [Abstract][Full Text] [Related]
28. APhL antibody ELISA as an alternative to anticardiolipin test for the diagnosis of antiphospholipid syndrome.
Suh-Lailam BB; Cromar A; Davis KW; Tebo AE
Int J Clin Exp Pathol; 2012; 5(3):210-5. PubMed ID: 22558475
[TBL] [Abstract][Full Text] [Related]
29. Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form.
Kolitz T; Shiber S; Sharabi I; Winder A; Zandman-Goddard G
Front Immunol; 2019; 10():941. PubMed ID: 31134062
[TBL] [Abstract][Full Text] [Related]
30. Relevance of non-criteria antiphospholipid antibodies titers among patients with antiphospholipid syndrome and patients with systemic lupus erythematosus.
Urrego-Callejas T; Hernández A; Ruiz Giraldo S; Frade-Sosa B; Vanegas-García AL; Muñoz CH; Rua C; Duque Botero J; González LA; Vásquez G; Gómez-Puerta JA
Reumatol Clin (Engl Ed); 2023 Apr; 19(4):197-203. PubMed ID: 37061281
[TBL] [Abstract][Full Text] [Related]
31. Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome.
Kopytek M; Natorska J; Undas A
Lupus; 2018 Apr; 27(5):812-819. PubMed ID: 29338587
[TBL] [Abstract][Full Text] [Related]
32. The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.
Bećarević M; Stojanović L; Ignjatović S; Dopsaj V
Clin Rheumatol; 2016 May; 35(5):1361-5. PubMed ID: 26971791
[TBL] [Abstract][Full Text] [Related]
33. Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies.
Radin M; Barinotti A; Cecchi I; Foddai SG; Rubini E; Roccatello D; Menegatti E; Sciascia S
J Clin Pathol; 2023 Dec; 76(12):839-846. PubMed ID: 36100400
[TBL] [Abstract][Full Text] [Related]
34. Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre.
Barilaro G; Coloma-Bazan E; Chacur A; Della Rocca C; Perez-Isidro A; Ruiz-Ortiz E; Viñas O; Tàssies Penella D; Reverter JC; Molina Andujar A; Cervera R; Espinosa G
Autoimmun Rev; 2022 Dec; 21(12):103208. PubMed ID: 36202304
[TBL] [Abstract][Full Text] [Related]
35. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository.
de Azevedo Lopes E; Balbi GGM; Tektonidou MG; Pengo V; Sciascia S; Ugarte A; Belmont HM; Gerosa M; Fortin PR; Lopez-Pedrera C; Ji L; Cohen H; de Jesús GR; Branch DW; Nalli C; Petri M; Rodriguez E; Kello N; Ríos-Garcés R; Knight JS; Atsumi T; Willis R; Bertolaccini ML; Erkan D; Andrade D;
Adv Rheumatol; 2021 Oct; 61(1):64. PubMed ID: 34711275
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
[TBL] [Abstract][Full Text] [Related]
37. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
38. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
39. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Domingues V; Chock EY; Dufrost V; Risse J; Seshan SV; Barbhaiya M; Sartelet H; Erkan D; Wahl D; Zuily S
Autoimmun Rev; 2022 Oct; 21(10):103158. PubMed ID: 35907609
[TBL] [Abstract][Full Text] [Related]
40. Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome.
Parkpian V; Verasertniyom O; Vanichapuntu M; Totemchokchyakarn K; Nantiruj K; Pisitkul P; Angchaisuksiri P; Archararit N; Rachakom B; Ayurachai K; Janwityanujit S
Clin Rheumatol; 2007 Oct; 26(10):1663-70. PubMed ID: 17332980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
